Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP.

Following the PACIFIC trial, durvalumab has been approved by the European Medicines Agency (EMA) for consolidation of locally advanced PD-L1-positive NSCLC after chemoradiotherapy (CRT). Patients were treated with durvalumab in the EAP from 22.11.2017 to 15.10.2018 allowing analysis of its efficacy and safety. 211 patients were registered by 90 German centres. Data were collected retrospectively by questionnaire and queries. 56 centres reported data on 126 patients who actually received at least one cycle of durvalumab. In contrast to the PACIFIC-trial population, some patients with oligometastatic disease and a history of autoimmune disease are included in the EAP population. Information on PD-L1 status was obtained for 111 patients. Baseline data include age, gender, ECOG, stage (IASLC 8th ed.), and smoking history. Treatment data include mode of chemoradiotherapy, used chemotherapy agent, and duration of durvalumab therapy. Adverse evants were documented according to CTAEC 5.0. Data were analysed for progression-free survival (PFS), overall survival (OS), and adverse events (AE). The results were published in Lung Cancer [1].

Informations de copyright

© 2020 The Author(s).

Déclaration de conflit d'intérêts

Martin Faehling received speaker's honoraria and participated as PI in clinical trials of AstraZeneca, Roche, MSD, and BMS. Christian Schumann received speaker's honoraria and participated in clinical trials by AstraZeneca, BMS, Boehringer, MSD, Pfizer, Roche, Takeda. Petros Christopoulos received research funding from AstraZeneca, Novartis, Roche, Takeda, and advisory board/lecture fees from AstraZeneca, Boehringer Ingelheim, Chugai, Novartis, Pfizer, Roche, Takeda. Petra Hoffknecht does not report any COIs. Jürgen Alt received speaker's honoraria by AstraZeneca. Marlitt Horn does not report any COIs. Stephan Eisenmann received speaker's honoraria by AstraZeneca. Anke Schlenska-Lange does not report any COIs. Philipp Schütt does not report any COIs. Felix Steger does not report any COIs. Wolfgang M. Brückl received honoraria for consulting from AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Lilly, MSD, Pfizer and Roche Pharma. Daniel C. Christoph received speaker's honoraria and participated as PI in clinical trials of AstraZeneca, Roche, MSD, Boehringer, and BMS. The results of our study were not influenced by the reported competing interests.